fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Povidone - iodine

All products: not a benefit

Betadine · PIN 00158348 · 10% · Top Sol

Listed, not a benefitOntario PIN; no Health Canada record under this code
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
1 brand, same coverage
Betadine · DIN 00158348 Manufacturer: Purdue Pharma; listing date 1996-10-01 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Re-check Health Canada status and shortages (live)

Betadine: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 00158348)

Source record
DIN 00158348: Betadine Raw flags: notABenefit=Y, sec3=Y, selfMed=Y Item: 840416007; group id 832; item number 2025; lccId None; manufacturer id PFP Source form: Top Sol; strength: 10% Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; self-medication (OTC-type) product Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00158348 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Interchangeable products
Proviodine · DIN 00172944 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00158348
Shortage record checked October 6, 2026

Proviodine · DIN 00172944 · 10% · Top Sol

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1999-04-08 — choose a marketed DIN from the same-category list.Discontinued April 8, 1999 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1999-04-08 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 1999-04-08 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Proviodine · DIN 00172944 Manufacturer: Rougier Pharma, Division of Ratiopharm Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 1999-04-08 · brand IODOVET SOLUTION · ATC not recorded · form Solution · route Topical · ingredients POVIDONE-IODINE 10 %/% · company Rougier pharma division of ratiopharm inc · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product record

Proviodine: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00172944)

Source record
DIN 00172944: Proviodine Raw flags: notABenefit=Y, sec3=Y, selfMed=Y Item: 840416007; group id 832; item number 2025; lccId None; manufacturer id ROG Source form: Top Sol; strength: 10% Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; self-medication (OTC-type) product Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00172944 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=332
Interchangeable products
Betadine · DIN 00158348 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00172944
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since April 8, 1999 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (84:04:16 Other Anti-Infectives) and how they are covered

Matched class: 84:04:16 Other Anti-Infectives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: METRONIDAZOLE & NYSTATIN, SILVER SULFADIAZINE Some products covered without a code (check the product listing): METRONIDAZOLE 84:04:16 Other Anti-Infectives

METRONIDAZOLE

· 5 products · General benefit (3), Off-Formulary Interchangeable, not an ODB benefit (2) · strengths: 1%, 0.75%, 10% · Top Cr, Top Gel, Vag Cr-App

METRONIDAZOLE & NYSTATIN

· 2 products · General benefit · strengths: 500mg & 100000U/g, 500mg & 100000U · Vag Cr-App, Vag Sup

SILVER SULFADIAZINE

· 2 products · General benefit · strengths: 1% · Cr, Cr-50g Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 84:04:16
Full class listing Related classes: 84:04:04 Antibiotics, 84:04:08 Fungicides, 84:04:12 Parasiticides Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found

Other review policies

For Betadine, Proviodine: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026